Urolithin A Supplementation in Middle-aged Adults With Obesity

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

May 14, 2025

Study Completion Date

May 14, 2025

Conditions
ObesityVascular DementiaCognitive Impairment
Interventions
DIETARY_SUPPLEMENT

Urolithin A

Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).

OTHER

Placebo

Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).

Trial Locations (1)

73117

Translational GeroScience Laboratory - O'Donoghue Research Building, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT05921266 - Urolithin A Supplementation in Middle-aged Adults With Obesity | Biotech Hunter | Biotech Hunter